The CCR6–CCL20 signaling pathway could be a potential therapeutic target for autoimmune diseases.36,37 Some inhibitors targeting CCR6 have also been studied in disease models, but not in LCH models.41,42 The findings of this study provide a theoretical basis for the study of CCR6 inhibitors in LCH disease models, promoting the development of LCH-targeted drugs. This evidence concerns the gene CCL20 and Langerhans cell histiocytosis.